key: cord-1037100-ye7y2d8z
authors: Wooding, Denise J.; Bach, Horacio
title: Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks
date: 2020-08-11
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.08.005
sha: 2cc7ef79cdeb7b745f9a061b67344a455141b5bd
doc_id: 1037100
cord_uid: ye7y2d8z

BACKGROUND: There is currently no treatment known to alter the course of COVID-19. Convalescent plasma has been used to treat a number of infections during pandemics, including SARS-CoV, MERS-CoV, and now COVID-19. OBJECTIVES: To summarize the existing literature and registered clinical trials on the efficacy and safety of convalescent plasma for treating coronaviruses, and discuss issues of feasibility, and donor and patient selection. SOURCES: A review of articles published in PubMed was performed on July 13, 2020, to summarize the currently available evidence in human studies for convalescent plasma as a treatment for coronaviruses. The World Health Organization International Clinical Trials Registry and clinicaltrials.gov were searched to summarize the currently registered randomized clinical trials for convalescent plasma in COVID-19. CONTENT: There were sixteen COVID-19, four MERS-CoV, and five SARS-CoV reports describing convalescent plasma use in humans. There were two randomized control trials, both of which were for COVID-19 and were terminated early. Most COVID-19 reports described a potential benefit of convalescent plasma on clinical outcomes in severe or critically ill patients with few immediate adverse events. However, there were a number of limitations, including the concurrent use of antivirals, steroids, and other treatments, small sample sizes, lack of randomization or control groups, and short follow-up time. Data from SARS-CoV and COVID-19 suggest that earlier administration likely yields better outcomes. The ideal candidates for recipients and donors are not known. Still, experience with prior coronaviruses tells us that antibodies in convalescent patients are probably short-lived. Patients who had more severe disease and who are earlier in their course of recovery may be more likely to have adequate titres. Finally, a number of practical challenges were identified. IMPLICATIONS: There is currently no effective treatment for COVID-19, and preliminary trials for convalescent plasma suggest there may be some benefits. However, research to date is at high risk of bias, and randomized control trials are desperately needed to determine the efficacy and safety of this therapeutic option.

disease and who are earlier in their course of recovery may be more likely to have adequate 22

titres. Finally, a number of practical challenges were identified. 23

Implications: There is currently no effective treatment for COVID-19, and preliminary trials for 24 convalescent plasma suggest there may be some benefits. However, research to date is at high 25 risk of bias, and randomized control trials are desperately needed to determine the efficacy and Similarly, hydroxychloroquine had promising initial results in non-randomized studies, but more 36 recent reports highlighted less benefit and even possible harm [8-10]. Since vaccines and 37 effective therapies for are not yet available, it is clear that additional clinical trials 38 and global action are required [11] . 39 Convalescent plasma has been used for decades to prevent and treat infectious diseases where 40 no specific treatment is available [12] . The use of convalescent plasma involves transfusing 41 plasma collected from patients who have already recovered from an illness, in an attempt to 42 transfer neutralizing antibodies and confer passive immunity [13] . The potential efficacy of 43 convalescent plasma was first described during the Spanish influenza pandemic of the early 44

1900s [14] . Since then, convalescent plasma has been used to attempt to treat a wide range of 45 viral infections, including measles, parvovirus B19, H1N1, Ebola, and some coronaviruses 46 [12, 15, 16] . Among the many coronaviruses that are only mildly pathogenic to humans, there are 47 respiratory syndrome coronavirus (MERS-CoV), and the 2019 novel coronavirus (SARS-CoV-2) 50 causing COVID-19 disease (Table 1 ) [15, [17] [18] [19] . 51

Other than two trials that were published after being terminated early [20, 21] , there is a lack 52 of randomized control trials investigating convalescent plasma as a therapy for coronaviruses, 53 though observational studies have reported some promising benefits [15, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Therefore, the 54 purpose of this review is to summarize the literature and identify areas for future focus regarding 55 the use of convalescent plasma to treat coronaviruses (SARS-CoV, MERS-CoV, and in 56 particular, COVID-19). A PubMed search was conducted on July 13, 2020, to examine the 57 literature published in English with no date limitations. Search terms included "coronavirus 58 convalescent patients", "MERS-CoV convalescent plasma", "SARS-CoV convalescent plasma", 59

and "COVID-19 convalescent plasma". Studies describing the use of convalescent plasma as a 60 treatment for one of these three coronaviruses in humans were included in the primary literature 61 described in Table 2 . Primary articles that were not returned in the initial search, but which were 62 cited by reviews or meta-analyses from the initial search, are also included. Additional searches 63 were conducted to add to the discussion of topics explored herein: efficacy, risks, patient 64 selection, donor selection and feasibility. 65

In addition, searches were performed on clinicaltrials.gov and on the World Health 66

Organization International Clinical Trials Registry platform on July 13, 2020, to summarize the 67 currently registered randomized clinical trials for convalescent plasma in COVID-19. The 68 following search terms were used with no date limitations for clinicaltrials.gov: Condition = 69 COVID-19, other terms = "convalescent plasma" randomized, study type = "interventional 70 studies." This search returned 59 results, of which 56 were randomized control trials for 71 convalescent plasma and are included herein. In addition, the WHO platform was searched using 72 the following terms: "COVID-19" and "randomized" and "convalescent plasma", which returned 73 51 results, of which 15 were not registered on clinicaltrials.gov, and of which 13 were 74 randomized clinical trials for convalescent plasma. These trials are summarized in Table 3 in 75 order of the primary completion date. 76

Reports of efficacy and safety of convalescent plasma for treatment of prior coronaviruses 78 A summary of the primary literature describing the use of convalescent plasma is found in of symptom onset) were significantly more likely to be discharged before day 22 (58% vs. 16%) 92 and trended toward lower mortality (6.3% vs. 21.9%, p=0.08) than those who received treatment 93 after day 14 [24] . Although there were many limitations, these data identified convalescent 94 plasma therapy as a potential avenue for coronavirus treatment during an outbreak. A meta-95 analysis which included SARS-CoV as well as non-coronaviruses (H1N1pdm09, H5N1 and 96 J o u r n a l P r e -p r o o f H1N1) identified a 75% reduction in the odds of mortality among patients treated with 97 convalescent plasma or serum with no serious adverse events or complications, though these 98 studies were deemed to be at moderate-to-high risk of bias [43] . and were receiving mechanical ventilation and various steroids and antivirals. Approximately 105 one week after infusion, patients exhibited normalized body temperature, and improved 106 P AO2 /F IO2 and Sequential Organ Failure Assessment (SOFA) scores. However, at the time the 107 study was completed, two patients remained hospitalized, and although their SOFA scores were 108 markedly improved, their ultimate clinical course was not followed up. This was the first study 109 to report a promising outcome of convalescent plasma for treating COVID-19, but similar to 110 most observational studies described herein, there was no control group, and it is unclear whether 111 patients would have improved without the transfusion, or if their improvement was more related 112 to one of the other therapeutic agents they received. 113

Other early studies studied six convalescent plasma-treated COVID-19 patients in China, 114 and described a benefit in terms of viral clearance and longer survival times, but this did not 115 translate to a mortality benefit compared to those not receiving convalescent plasma [36] . Also, 116 hopeful signals that can be gleaned from what was likely an underpowered study [46] . Although 163 it was not the primary endpoint, there was a significant effect of treatment after patients were 164 J o u r n a l P r e -p r o o f stratified into subgroups, leading those with severe disease to have a significantly shorter time to 165 clinical improvement with convalescent plasma (nearly 5 days), while those with the life-166

threatening disease did not [20] . This is similar to the study in a cohort of 138 treated patients, 167 convalescent plasma benefited those with severe but not critical illness [44] , and is in alignment 168

with the general principle that convalescent plasma is more effective when administered early in 169 the disease course [47] . In addition, while findings did not reach statistical significance, the trend 170 for a modest improvement in mortality (24% vs. 16%) is useful for informing power calculations 171 in upcoming randomized control trials [46] . 172

The second randomized trial, conducted in the Netherlands, was halted after 86 patients 173

were enrolled because the vast majority of patients were found to have baseline neutralizing 174 antibody titres that were comparable to donor levels [21] . Thus, somewhat unsurprisingly, there 175 was no effect of treatment on mortality, hospital length of stay, or disease severity [21] . The 176 important lessons from this study are that hospitalized patients may not benefit if they already 177 have high baseline neutralizing titres, and future studies should consider investigating patient 178 populations that are less likely to have high titres and who could benefit from additional 179 treatment, such as outpatients who are at high risk of disease progression. In addition, testing 180 potential recipients for existing antibody titres before treatment is not in the current protocol for 181 most trials but is an important consideration [21] . 182 183

There are a number of known and theoretical risks of convalescent plasma. Known risks include 185 risks associated with any blood product, such as transmission of infectious diseases including the 186 potential pathogen being treated, and reactions to serum including serum sickness [37, 48, 49] . 187

With modern screening of donor plasma for blood-borne pathogens and blood type, these risks 188 are low [48] . Nonetheless, TRALI is a life-threatening complication and this issue of potential 189 toxicity must be considered, especially in those at increased risk due to significant lung injury 

Convalescent plasma: new evidence for an old 333 therapeutic tool?

Accessed 1

Use of human immunoglobulins as an anti-infective treatment: the 336 experience so far and their possible re-emerging role

Meta-Analysis: Convalescent Blood Products 339 for Spanish Influenza Pneumonia: A Future H5N1 Treatment?

Treatment of 5 Critically Ill Patients With COVID-19 With 342 Convalescent Plasma

Evaluation of Convalescent Plasma for 345

Ebola Virus Disease in Guinea

Genetic Recombination, and Pathogenesis of 347 Coronaviruses

Severe acute respiratory syndrome

Isolation of a 351 Novel Coronavirus from a Man with Pneumonia in Saudi Arabia

Effect of Convalescent Plasma Therapy on Time to Clinical 354 Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized 355 Clinical Trial

Convalescent Plasma for COVID-19. A 358 randomized clinical trial

Challenges of convalescent plasma infusion therapy in Middle 362 East respiratory coronavirus infection: a single centre experience

Clinical Presentation and Outcomes of Middle East 365 Respiratory Syndrome in the Republic of Korea

Use of convalescent plasma therapy in SARS

Retrospective comparison of convalescent plasma with 369 continuing high-dose methylprednisolone treatment in SARS patients

Experience of using convalescent plasma for severe acute 372 respiratory syndrome among healthcare workers in a Taiwan hospital

Treatment of severe acute respiratory syndrome with 375 convalescent plasma

Letter to the editor

Severe refractory COVID-19 patients 378 responding to convalescent plasma; A case series

Life-saving effect of convalescent 380 plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia

Early safety indicators of COVID-19 convalescent 383 plasma in 5,000 patients

Convalescent plasma treatment of severe COVID-19: A 386 matched control study. Infectious Diseases (except HIV/AIDS)

Use of Convalescent Plasma in Hospitalized 389 Patients with Covid-19 -Case Series

First case of convalescent plasma transfusion in a 391 child with COVID-19-associated severe aplastic anemia

Convalescent Plasma Therapy in Coronavirus 393 Disease 2019: a Case Report and Suggestions to Overcome Obstacles

Effect of Convalescent Plasma Therapy on Viral Shedding and 396 Survival in COVID-19 Patients

Effectiveness of convalescent plasma therapy in severe COVID-19 398 patients

Treatment with convalescent plasma for COVID-19 patients in 400

Treatment With Convalescent Plasma for Critically Ill Patients 403 With SARS-CoV-2 Infection

Use of Convalescent Plasma Therapy in Two COVID-19 Patients 405 with Acute Respiratory Distress Syndrome in Korea

Predictors of mortality in Middle East respiratory 407 syndrome (MERS)

Possible Transfusion-Related Acute Lung Injury Following 409 Convalescent Plasma Transfusion in a Patient With Middle East Respiratory Syndrome

The Effectiveness of Convalescent 412 Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory 413 Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis

Treatment 416 and preliminary outcomes of 150 acute care patients with COVID-19 in a rural health 417 system in the Dakotas

419 Convalescent plasma transfusion for the treatment of COVID-19: Systematic review

A Randomized Trial of Convalescent Plasma for COVID-422 19-Potentially Hopeful Signals

Return to the Past: The Case for Antibody-Based Therapies in 425 Infectious Diseases

The convalescent sera option for containing COVID-19

Deployment of convalescent plasma for the 429 prevention and treatment of COVID-19

Collecting and 432 evaluating convalescent plasma for COVID-19 treatment: why and how?

Transfusion-related acute lung injury (TRALI): a clinical 435 review with emphasis on the critically ill

Tetro JA. Is COVID-19 receiving ADE from other coronaviruses?

Convalescent plasma as a potential therapy for COVID-19

Viral Kinetics and Antibody Responses in Patients with COVID-19. 441 Infectious Diseases (except HIV/AIDS)

Feasibility of Using Convalescent Plasma Immunotherapy 444 for MERS-CoV Infection, Saudi Arabia

Use of Convalescent Whole Blood or Plasma Collected from 446 Patients Recovered from Ebola Virus Disease for Transfusion, as an Empirical Treatment 447 during Outbreaks. Interim Guidance for National Health Authorities and

Kinetics of Serologic Responses to MERS 450

58. CDC. Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens 452 Associated with Coronavirus Disease

MERS-CoV Antibody Responses 1 Year after 456 Symptom Onset, South Korea

Dynamic changes of serum SARS-Coronavirus IgG, pulmonary 458 function and radiography in patients recovering from SARS after hospital discharge

Disappearance of Antibodies to SARS-461

Associated Coronavirus after Recovery

Profiling Early Humoral Response to Diagnose Novel Coronavirus 463 Disease (COVID-19)

Accessed 2

63. Research C for BE and. Investigational COVID-19 Convalescent Plasma -Emergency INDs

Diagnosis and Management of 475 COVID-19 Disease

Immune responses in COVID-19 and potential vaccines: 477 Lessons learned from SARS and MERS epidemic